ミシガン州における食道腺癌の臨床試験
ミシガン州内の拠点で、食道腺癌に関する9件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 他21件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- 他61件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- University of Michigan, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
- University of Michigan Rogel Cancer Center, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06732388Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- University of Michigan, Ann Arbor
被験者募集中
18歳〜89歳 · 全性別 · 2026/09/11更新 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281Obeticholic Acid for Prevention in Barrett's Esophagus
- University of Michigan Rogel Cancer Center, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT04939051A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Henry Ford Health System, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2025/11/05更新 · NCT05563766ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。